Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004343413 | Lung | AIS | response to peptide hormone | 70/1849 | 414/18723 | 5.19e-06 | 2.48e-04 | 70 |
GO:004206013 | Lung | AIS | wound healing | 71/1849 | 422/18723 | 5.32e-06 | 2.52e-04 | 71 |
GO:190188811 | Lung | AIS | regulation of cell junction assembly | 41/1849 | 204/18723 | 7.76e-06 | 3.35e-04 | 41 |
GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
GO:006145812 | Lung | AIS | reproductive system development | 70/1849 | 427/18723 | 1.52e-05 | 5.50e-04 | 70 |
GO:000717912 | Lung | AIS | transforming growth factor beta receptor signaling pathway | 39/1849 | 198/18723 | 2.08e-05 | 7.12e-04 | 39 |
GO:004860811 | Lung | AIS | reproductive structure development | 69/1849 | 424/18723 | 2.23e-05 | 7.42e-04 | 69 |
GO:000836013 | Lung | AIS | regulation of cell shape | 32/1849 | 154/18723 | 3.75e-05 | 1.14e-03 | 32 |
GO:000166713 | Lung | AIS | ameboidal-type cell migration | 73/1849 | 475/18723 | 8.91e-05 | 2.20e-03 | 73 |
GO:000740911 | Lung | AIS | axonogenesis | 64/1849 | 418/18723 | 2.62e-04 | 5.04e-03 | 64 |
GO:009013211 | Lung | AIS | epithelium migration | 56/1849 | 360/18723 | 4.14e-04 | 7.14e-03 | 56 |
GO:004677711 | Lung | AIS | protein autophosphorylation | 39/1849 | 227/18723 | 4.30e-04 | 7.37e-03 | 39 |
GO:006156411 | Lung | AIS | axon development | 69/1849 | 467/18723 | 4.37e-04 | 7.41e-03 | 69 |
GO:001063211 | Lung | AIS | regulation of epithelial cell migration | 47/1849 | 292/18723 | 5.47e-04 | 8.65e-03 | 47 |
GO:009013011 | Lung | AIS | tissue migration | 56/1849 | 365/18723 | 5.85e-04 | 9.03e-03 | 56 |
GO:001063111 | Lung | AIS | epithelial cell migration | 55/1849 | 357/18723 | 5.89e-04 | 9.03e-03 | 55 |
GO:003599411 | Lung | AIS | response to muscle stretch | 8/1849 | 23/18723 | 1.12e-03 | 1.44e-02 | 8 |
GO:0018212 | Lung | AIS | peptidyl-tyrosine modification | 56/1849 | 378/18723 | 1.35e-03 | 1.68e-02 | 56 |
GO:000717812 | Lung | AIS | transmembrane receptor protein serine/threonine kinase signaling pathway | 53/1849 | 355/18723 | 1.51e-03 | 1.82e-02 | 53 |
GO:001076111 | Lung | AIS | fibroblast migration | 12/1849 | 47/18723 | 1.63e-03 | 1.87e-02 | 12 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa015223 | Cervix | CC | Endocrine resistance | 28/1267 | 98/8465 | 3.82e-04 | 1.87e-03 | 1.11e-03 | 28 |
hsa0510020 | Cervix | CC | Bacterial invasion of epithelial cells | 23/1267 | 77/8465 | 6.25e-04 | 2.93e-03 | 1.73e-03 | 23 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTK2 | SNV | Missense_Mutation | | c.1688N>T | p.Gly563Val | p.G563V | Q05397 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTK2 | SNV | Missense_Mutation | rs542542126 | c.2696N>T | p.Ala899Val | p.A899V | Q05397 | protein_coding | tolerated(0.07) | possibly_damaging(0.652) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTK2 | SNV | Missense_Mutation | | c.755N>T | p.Arg252Ile | p.R252I | Q05397 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTK2 | SNV | Missense_Mutation | novel | c.1834A>G | p.Met612Val | p.M612V | Q05397 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTK2 | SNV | Missense_Mutation | rs374554975 | c.140G>A | p.Ser47Asn | p.S47N | Q05397 | protein_coding | tolerated_low_confidence(0.21) | benign(0) | TCGA-BH-A18S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTK2 | SNV | Missense_Mutation | | c.121N>T | p.His41Tyr | p.H41Y | Q05397 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
PTK2 | SNV | Missense_Mutation | | c.1648N>T | p.Arg550Trp | p.R550W | Q05397 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PTK2 | SNV | Missense_Mutation | novel | c.1166N>C | p.Val389Ala | p.V389A | Q05397 | protein_coding | tolerated(0.33) | benign(0.412) | TCGA-D8-A73X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTK2 | SNV | Missense_Mutation | | c.1790N>T | p.Arg597Leu | p.R597L | Q05397 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-E9-A1RA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTK2 | SNV | Missense_Mutation | | c.1456N>G | p.Leu486Val | p.L486V | Q05397 | protein_coding | deleterious(0) | benign(0.178) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | SNS-314 | SNS-314 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | inhibitor | CHEMBL1084546 | PF-00562271 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | RG-1530 | RG-1530 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | BI-853520 | BI-853520 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | PF-562271 | PF-00562271 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | PF-04554878 | DEFACTINIB | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | GW843682X | GW843682X | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | inhibitor | CHEMBL3544967 | GSK-2256098 | |
5747 | PTK2 | TYROSINE KINASE, DRUGGABLE GENOME, KINASE, G PROTEIN COUPLED RECEPTOR, ENZYME | | 1,2,4-triazolo[1,5a]pyridine derivative 1 | | |